#USA #Bedford #Instylla #Embrace Hydrogel #Sean Boyle

Instylla Appoints Sean Boyle as New CEO

Instylla, Inc., a leading clinical-stage company specializing in peripheral vascular embolization, recently made a significant move by appointing Sean Boyle as its new Chief Executive Officer. This appointment comes during a pivotal time for the company, which is focused on launching its innovative embolization solutions, including the Embrace™ Hydrogel Embolic System.

Sean Boyle brings over 15 years of extensive experience in the medical device industry. Previously, he held the position of Vice President and General Manager of Peripheral Intervention at Becton Dickinson. During his tenure, he managed a substantial global portfolio of nearly $1 billion in revenue. Boyle's leadership skills and impressive track record in transforming various business units will be vital for Instylla as it enters this essential phase of commercialization.

"I am honored to join Instylla at such a crucial moment in its journey," said Boyle. He emphasized the potential of Instylla's next-generation embolization platform as a game-changer in the treatment of conditions such as hypervascular tumors and the management of significant hemorrhages, stating, "This technology has the promise to improve patient outcomes significantly."

Amar Sawhney, the Chairman of the Board at Instylla, expressed his enthusiasm about Boyle's appointment, stating that his extensive expertise and proven leadership qualities make him exceptionally well-suited to steer the company forward. Sawhney, who founded Instylla and served as CEO until this new appointment, remains committed to supporting the team through this transformative time.

A Bright Future for Instylla
Founded in 2017 and headquartered in Bedford, Massachusetts, Instylla is at the forefront of developing innovative resorbable embolic agents for interventional radiology. The company's focus is on interventional oncology and managing hemorrhages within the peripheral vasculature. With recent funding secured, Instylla is well-equipped as it navigates through the commercialization of its products and aims to make a lasting impact on patient care.

In addition to Boyle's appointment, Instylla has plans for expansion and further innovation. With the Embrace™ Hydrogel Embolic System leading the effort, the company aims to enhance the effectiveness of treatments within the field significantly. These advancements will not only benefit clinicians dealing with complex cases but also significantly improve the quality of life for patients.

Looking Ahead
As Instylla ramp up operations, Boyle will work closely with investors, the board, and an outstanding team of professionals to accelerate the company’s momentum. His strategic insights and history of scaling medical device businesses will play an important role in deciding the future direction of Instylla as it grows into its next phase.

In conclusion, the appointment of Sean Boyle as CEO marks a crucial step for Instylla. The company is positioned to leverage his comprehensive experience to advance its goals in delivering innovative health solutions and improving patient outcomes. As the healthcare landscape evolves, Instylla is ready to make waves, spearheaded by Sean Boyle's vision and leadership.